• HOME
  • ABOUT
  • AWARDEES
    • Automatic Detection and Tracing
    • Chemosensory Testing
    • Exosome-Based
    • Multimodal Surveillance
    • Novel Biosensing and VOC
    • PreVAIL kIds
    • SCENT
    • Wastewater
    • NIEHS Diagnostic/Prognostic RNAseq
  • RESOURCES
    • DATA Tools
  • EVENTS
  • COMMUNICATIONS
  • FAQs
  • CONTACT
RADx Radical
  • HOME
  • ABOUT
  • AWARDEES
    • Automatic Detection and Tracing
    • Chemosensory Testing
    • Exosome-Based
    • Multimodal Surveillance
    • Novel Biosensing and VOC
    • PreVAIL kIds
    • SCENT
    • Wastewater
    • NIEHS Diagnostic/Prognostic RNAseq
  • RESOURCES
    • DATA Tools
  • EVENTS
  • COMMUNICATIONS
  • FAQs
  • CONTACT
Search site...
RADx℠ Radical > News > FDA: SARS-CoV-2 mutations impact on COVID-19 tests

FDA: SARS-CoV-2 mutations impact on COVID-19 tests

December 10, 2021

This page has information about COVID-19 diagnostic tests with relation to viral mutations, such as the Omicron variant.

https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests

Share:
Contact us
radx-rad-admin@ucsd.edu

© Copyright 2021   |   RADx Radical   |   All Rights Reserved
The RADx-rad DCC is funded by NIH (U24LM013755)